It regulates excessive glutamate activity in the brain, helping preserve cognitive and daily functioning. The product is supplied as tablets for oral use.
It regulates excessive glutamate activity in the brain, helping preserve cognitive and daily functioning. The product is supplied as tablets for oral use.
Memantine, the active substance in Memantine, is an NMDA-receptor antagonist used for moderate to severe Alzheimer’s disease.
The active substance is memantine. It is supplied as tablets for oral use and acts as an NMDA-receptor antagonist, regulating excessive glutamate activity in the brain. Memantine is used for moderate to severe Alzheimer’s disease.
Memantine is indicated for moderate to severe Alzheimer’s disease. It may be used when dementia has progressed beyond mild cognitive impairment and symptoms interfere with daily activities, safety, communication, or independent decision-making.
Alzheimer’s dementia can affect:
Memantine may also be used in some treatment plans involving mixed dementia, where Alzheimer’s pathology occurs alongside vascular or other cognitive disease. The prescribing decision depends on the clinical diagnosis and the person’s level of impairment.
Mild cognitive impairment is different from moderate to severe dementia. A person with mild cognitive impairment may have measurable memory difficulties while retaining most independent daily functions. Memantine is not routinely used for every person with mild cognitive impairment.
Frontotemporal dementia has a different clinical pattern and does not automatically qualify for memantine treatment. Language-led symptoms, personality change, and executive dysfunction require a separate specialist assessment. The medicine should be used for the diagnosed indication rather than for memory loss of uncertain cause.
The EMA describes memantine as a treatment for moderate to severe Alzheimer’s disease, while treatment decisions in Ireland sit within specialist prescribing practice and national medicines governance, including the HPRA framework. [2]
The amount of Memantine used and the frequency of administration depend on the purpose of treatment and are agreed with a doctor or pharmacist. Memantine is commonly started at a low dose and increased in stages, allowing the nervous system to adjust.
A typical clinical plan includes:
The tablet should be swallowed with water. It may be taken with food or on an empty stomach. Taking it at the same time each day can help maintain a consistent routine and makes missed doses easier to identify.
If a dose is missed, the usual approach is to take the next scheduled dose rather than taking extra tablets. A prolonged interruption may require re-titration, especially when several doses have been missed. The clinician or pharmacist should determine the restart plan.
Slow titration reduces the chance of dizziness, headache, constipation, confusion, sleep disturbance, and agitation. Older adults may be more sensitive to changes in medicines because kidney clearance, hydration, balance, and blood pressure can vary from day to day.
Kidney function deserves attention. Memantine is eliminated mainly through the kidneys, so reduced renal clearance can raise exposure. A history of kidney disease, recurrent dehydration, or significant changes in fluid intake should be included in the medication review.
Memantine is not suitable for a person with a known serious allergy to memantine or any excipient in the prescribed formulation.
NOT for you if a prescriber has identified a serious allergy to memantine or an excipient, or if the diagnosis is not established; specialist review is needed for severe kidney disease.
Memantine is often tolerated without severe complications, though unwanted effects can affect balance, alertness, digestion, and behaviour. Side effects may be more apparent during initiation or after a dose increase.
Common or recognised reactions include:
Dizziness is clinically relevant because it can increase the risk of falls. A person who becomes unsteady after starting treatment should avoid walking unaided on stairs or uneven ground until the response is clear.
Constipation may worsen in people who already drink little, eat very little fibre, take opioid pain medicines, or have limited mobility. Persistent constipation, abdominal pain, vomiting, or marked abdominal swelling needs prompt medical assessment.
Urgent medical attention is required for facial or throat swelling, breathing difficulty, widespread rash, collapse, severe confusion, or sudden marked changes in behaviour. These symptoms may indicate hypersensitivity or another serious reaction.
Neuroleptic malignant syndrome is rare but serious. Warning features include high fever, severe muscle rigidity, altered consciousness, heavy sweating, and rapid changes in pulse or blood pressure. This requires emergency assessment.
Memantine belongs to the class of uncompetitive N-methyl-D-aspartate (NMDA)-receptor antagonists. Its active substance is memantine, also known pharmacologically as memantine hydrochloride or Memantine HCl. It acts within the central nervous system (CNS), where glutamate is the main excitatory neurotransmitter.
Under normal conditions, glutamate supports learning, memory formation, attention, and communication between nerve cells. NMDA receptors help transmit these signals when activated in a controlled way. Excessive or prolonged NMDA activity can allow too much calcium to enter nerve cells, contributing to excitotoxic stress.
Memantine binds within the NMDA receptor channel in a voltage-dependent manner. This reduces pathological receptor activation while allowing normal, brief glutamate signalling to continue. The distinction matters: the aim is not to switch off glutamate transmission, but to reduce harmful background stimulation. [1]
Several practical errors can reduce tolerability or make treatment appear ineffective:
One easily missed detail is hydration. Dehydration can worsen dizziness, constipation, confusion, and kidney-related medicine exposure at the same time.
Another is the difference between a missed dose and a treatment interruption. Missing one tablet may require a simple return to the next scheduled dose; several missed days can require a safer restart plan.
Memantine and cholinesterase inhibitors act on different pathways. Memantine regulates excessive NMDA-receptor activity, while cholinesterase inhibitors increase the availability of acetylcholine, a neurotransmitter involved in memory and attention.
| Treatment category | Main pharmacological target | Typical clinical role |
|---|---|---|
| Memantine | NMDA receptor and glutamate signalling | Moderate to severe Alzheimer’s disease |
| Cholinesterase inhibitors | Acetylcholinesterase and acetylcholine signalling | Alzheimer’s disease and selected related dementias |
| Combined treatment | NMDA and cholinergic pathways | Selected people with more advanced Alzheimer’s disease |
Donepezil, also known by the brand name Aricept, and rivastigmine are cholinesterase inhibitors. They can cause nausea, diarrhoea, reduced appetite, weight loss, slow heart rate, or fainting in susceptible patients. Memantine has a different adverse-effect pattern, with dizziness, headache, constipation, and confusion among the recognised problems.
Combination therapy may be prescribed when a person has progressed to moderate or severe Alzheimer’s disease and the clinician believes that maintaining both mechanisms is appropriate. Adding Memantine does not guarantee a noticeable improvement, and treatment should be judged by cognition, function, behaviour, caregiver burden, and tolerability.
The WHO recognises dementia as a clinical syndrome with multiple causes, rather than a single disease with one universal treatment. The FDA and NICE also publish guidance relevant to treatment decisions in dementia. [3]
In clinical practice, doctors usually assess more than memory scores. They look at dressing, eating, managing familiar objects, recognising relatives, communicating needs, and coping with ordinary household routines.
A physician may continue Memantine when decline appears slower, daily functioning remains steadier, or behavioural symptoms become easier to manage without unacceptable adverse effects. The medicine is less useful when treatment is judged only by whether a person becomes visibly sharper within a few days.
Caregivers often notice treatment changes before the patient does. A medication diary can record sleep, falls, appetite, constipation, agitation, hallucinations, and ability to complete familiar tasks. This gives the clinician practical information for dose decisions.
Treatment review is needed when kidney function changes, fluid intake falls, a hospital admission occurs, or several new medicines are added. Memantine should not be increased simply because dementia symptoms fluctuate from one day to the next.
Dizziness is a recognised adverse effect of Memantine, especially during treatment initiation or after a dose increase. The EMA's 2024 product information identifies dizziness, headache, and confusion among reported reactions. A person who becomes unsteady should avoid unsupported walking and have the treatment reviewed rather than taking an additional dose. [4]
The best time depends on the prescribed schedule, sleep pattern, and whether the person develops daytime sleepiness or evening restlessness. The HPRA's 2024 product information supports medicine use according to the authorised product information and clinical prescription in Ireland. Taking Memantine at a consistent time, often in the morning when sleep disturbance occurs, can make the routine easier to manage. [5]
The prescriber should know about kidney disease, epilepsy, urinary problems, liver disease, falls, allergies, and every medicine or supplement being used. Medicines such as amantadine, ketamine, cimetidine, quinidine, triamterene, methazolamide, antipsychotics, and antimuscarinics may affect the treatment plan. The WHO's 2023 dementia guidance describes care as a coordinated process, so the patient’s diagnosis, functional abilities, and caregiver support also need review.
Memantine is generally used in adults with moderate to severe Alzheimer’s disease. Its routine use in children and adolescents is not established for this indication, and paediatric dementia presentations require specialist assessment. The EMA's 2024 information limits the authorised Alzheimer’s indication to the relevant adult population rather than recommending routine use under 18.
Memantine should only be used during pregnancy when a prescriber has judged that the expected benefit outweighs potential risk. Pregnancy planning, a positive pregnancy test, or breastfeeding should be discussed before treatment continues. The HPRA's 2024 product-information requirements and the European medicines framework require pregnancy and lactation considerations to be included in prescribing decisions, especially when clinical evidence is limited.
Memantine tablets may generally be taken with food or without food, provided the prescribed schedule is followed consistently. Food is not usually used to correct dizziness, confusion, or other adverse effects. The EMA's 2024 product information supports oral administration according to the prescribed regimen, while kidney function and interacting medicines remain more important factors for dose selection.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Based on 5 reviews
I used Memantine as part of my mother’s treatment plan for several months. The first week brought more dizziness, so the clinician kept the dose unchanged before increasing it. Her memory did not return, but she stayed with familiar routines for longer.
Several months 31 Oct 2026The tablets were easy to give in the morning. Constipation became noticeable during the second week and improved after the pharmacist reviewed her other medicines and daily fluids. The main benefit was less confusion during ordinary household tasks.
6 Nov 2026Memantine did not produce a sudden change. After about a month, conversations seemed slightly easier and evenings were less unsettled. There were two episodes of unsteadiness after an increase, so the treatment plan was adjusted.
About a month 10 Oct 2026I expected a stronger memory improvement than we saw. My father remained forgetful, and he complained of headaches during the early stage. The medicine was continued because he still managed some personal tasks independently.
19 Oct 2026The routine worked better when the tablet was given at the same time each day. A missed dose caused confusion about what to do next, so we stopped trying to compensate with an extra tablet and kept a written record instead.
22 Oct 2026
